🇺🇸 FDA
Pipeline program

CS1003, Placebo, LENVATINIB

CS1003-305

Phase 3 small_molecule active

Quick answer

CS1003, Placebo, LENVATINIB for Unresectable advanced hepatocellular carcinoma is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Unresectable advanced hepatocellular carcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials